Chemical modification of insulin in amyloid fibrils

被引:51
作者
Nilsson, MR [1 ]
Dobson, CM [1 ]
机构
[1] Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England
关键词
insulin; amyloid; deamidation; fibrils; symmetry;
D O I
10.1110/ps.0360403
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We have investigated the chemical modification of insulin under conditions that promote the conversion of the soluble protein into amyloid fibrils. The modifications that are incorporated into the fibrils include deamidation of Asn A21, Asn B3, and Gln B4. In order to prepare fibrils with minimal deamidation of these residues, the kinetics of aggregation were accelerated by seeding with aliquots of a solution containing preformed fibrils. The resulting fibrils were then reincubated to determine the extent to which chemical modification occurs in the fibril itself. The deamidation of Asn A21 in particular could be followed in detail. Deamidation of this residue in the fibrillar form of insulin was found to occur in only 52 +/- 5% of molecules. This result indicates that there are at least two different packing environments of insulin molecules in the fibrils and suggests that the characterization of chemical modifications may be a useful probe of the environment of polypeptide chains within amyloid fibrils.
引用
收藏
页码:2637 / 2641
页数:5
相关论文
共 27 条
[1]   Formation of insulin amyloid fibrils followed by FTIR simultaneously with CD and electron microscopy [J].
Bouchard, M ;
Zurdo, J ;
Nettleton, EJ ;
Dobson, CM ;
Robinson, CV .
PROTEIN SCIENCE, 2000, 9 (10) :1960-1967
[2]   CHEMICAL-STABILITY OF INSULIN .1. HYDROLYTIC DEGRADATION DURING STORAGE OF PHARMACEUTICAL PREPARATIONS [J].
BRANGE, J ;
LANGKJAER, L ;
HAVELUND, S ;
VOLUND, A .
PHARMACEUTICAL RESEARCH, 1992, 9 (06) :715-726
[3]   Toward understanding insulin fibrillation [J].
Brange, J ;
Andersen, L ;
Laursen, ED ;
Meyn, G ;
Rasmussen, E .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1997, 86 (05) :517-525
[4]   INSULIN AS AN AMYLOID-FIBRIL PROTEIN AT SITES OF REPEATED INSULIN INJECTIONS IN A DIABETIC PATIENT [J].
DISCHE, FE ;
WERNSTEDT, C ;
WESTERMARK, GT ;
WESTERMARK, P ;
PEPYS, MB ;
RENNIE, JA ;
GILBEY, SG ;
WATKINS, PJ .
DIABETOLOGIA, 1988, 31 (03) :158-161
[5]   The structural basis of protein folding and its links with human disease [J].
Dobson, CM .
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, 2001, 356 (1406) :133-145
[6]  
Du Vigneaud V, 1933, J BIOL CHEM, V102, P521
[7]   Modified-peptide inhibitors of amyloid β-peptide polymerization [J].
Findeis, MA ;
Musso, GM ;
Arico-Muendel, CC ;
Benjamin, HW ;
Hundal, AM ;
Lee, JJ ;
Chin, J ;
Kelley, M ;
Wakefield, J ;
Hayward, NJ ;
Molineaux, SM .
BIOCHEMISTRY, 1999, 38 (21) :6791-6800
[8]   ASSESSMENT OF GELLING IN INSULIN SOLUTIONS FOR INFUSION PUMPS [J].
HUTCHISON, KG .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1985, 37 (08) :528-531
[9]   The protofilament structure of insulin amyloid fibrils [J].
Jimenez, JL ;
Nettleton, EJ ;
Bouchard, M ;
Robinson, CV ;
Dobson, CM ;
Saibil, HR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (14) :9196-9201
[10]   In vivo conversion of racemized β-amyloid ([D-Ser26]Aβ1-40) to truncated and toxic fragments ([D-Ser26]Aβ25-35/40) and fragment presence in the brains of Alzheimer's patients [J].
Kubo, T ;
Nishimura, S ;
Kumagae, Y ;
Kaneko, I .
JOURNAL OF NEUROSCIENCE RESEARCH, 2002, 70 (03) :474-483